AD-MS Chips for Biofluids-Based Diagnosis of Alzheimer's Disease

AD-MS 芯片用于基于生物流体的阿尔茨海默病诊断

• 批准号: 9789132
• 负责人: DAOJING WANG
• 金额: $ 75万
• 依托单位: NEWOMICS, INC
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-01 至 2021-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9789132
• 关键词: Affect; Aging; Alzheimer' s Disease; American; Amyloid; Amyloid beta-Protein; Amyloidosis; Apolipoprotein E; Bioinformatics; Biological; Biological Assay; Biological Markers; Blood; Blood - brain barrier anatomy; Blood Plasma Volume; Blood specimen; Businesses; Cerebrospinal Fluid; Clinical; Clinical Data; Clinical Trials; Collaborations; Data Set; Dementia; Development; Diagnosis; Early Diagnosis; Frontotemporal Dementia; Human; Individual; Infusion procedures; Lipids; Magnetic Resonance Imaging; Measurement; Methods; Microfluidic Microchips; Molecular; Neurodegenerative Disorders; Pathway interactions; Patients; Phase; Plasma; Positron-Emission Tomography; Property; Proteomics; Reproducibility; Sampling; Sampling Studies; Scientist; Sensitivity and Specificity; Shotguns; Silicon; Small Business Innovation Research Grant; Speed; Technology; Testing; United States National Institutes of Health; Universities; Washington; base; biomarker panel; biomarker validation; blood-based biomarker; cohort; cost; differential expression; disease diagnosis; experimental study; improved; industry partner; innovation; mental state; metabolomics; minimally invasive; multiple omics; novel; peripheral blood; pre-clinical; prospective; protein expression; research and development; response; small molecule; targeted treatment; tau Proteins

Project Summary/Abstract Alzheimer's disease (AD) is a devastating neurodegenerative disease that affects more than 35 million people (including 5 million Americans) worldwide, and this number is expected to reach more than 115 million by the year 2050. Recent disappointing results from a large number of clinical trials for AD treatment further aggravate the problem. One major challenge is there is currently no blood-based biomarker for early diagnosis or target therapy of AD. The field is calling for transformative technologies and approaches. In response to PAS-17-064, Newomics Inc. proposes this SBIR Phase II project to complete development of its product, AD-MS chips and multiomics assays enabled by these microfluidic chips, for biofluids-based diagnosis of AD. The Phase II project is built upon the promising results generated from our Phase I project. In Phase I, we have developed the integrated silicon microfluidic chips as a high-throughput and multiplex platform for LC-MS-based multiomics assays. We have performed preliminary multiomics experiments on clinical samples using our unique platform. Furthermore, we have implemented statistical and bioinformatics methods to discover new biomarker panels and pathways and networks for early diagnosis of AD. In Phase II, we will optimize and validate our platform and multiomics assays with large cohorts of both retrospective and prospective clinical samples. Once developed, Newomics' integrated platforms and solutions will enable rapid, low-cost, reproducible, highly specific and sensitive multiplex measurements of human peripheral blood and CSF samples, and contribute to early diagnosis and target therapy of AD.

项目摘要/摘要 阿尔茨海默氏病（AD）是一种毁灭性的神经退行性疾病，影响超过3500万人 （包括500万美国人）在全球范围内，预计这一数字将超过1.15亿 2050年。最近的大量AD治疗临床试验的令人失望的结果进一步加剧 问题。一个主要挑战是目前尚无血液以早期诊断或靶标的生物标志物 AD治疗。该领域要求采用变革性技术和方法。响应PAS-17-064， Newomics Inc.提出了这个SBIR II期项目，以完成其产品的开发AD-MS芯片和 这些微流体芯片对基于生物流体的AD诊断进行了多组学测定。第二阶段项目 建立在我们第一阶段项目产生的有希望的结果之上。在第一阶段，我们开发了 集成的硅微流体芯片作为基于LC-MS的多层次的高通量和多重平台 测定。我们已经使用我们独特的平台在临床样本上进行了初步多素学实验。 此外，我们已经实施了统计和生物信息学方法来发现新的生物标志物面板 以及用于早期诊断AD的途径和网络。在第二阶段，我们将优化和验证我们的平台， 具有大量回顾性和前瞻性临床样本的多组分分析。一旦发展， Newomics的集成平台和解决方案将使快速，低成本，可重现，高度具体，并且 人类外周血和CSF样品的敏感多路复用测量，并有助于早期 AD的诊断和靶向治疗。